News & Events about Cullinan Oncology Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthat the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowens ...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthe U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ...
Globe Newswire
10 months ago
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, ...
Globe Newswire
12 months ago
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41% at 100 mg BID dose Continued favorable safety and tolerability profile observed in heavily pre-...